Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Allarity Therapeutics ( (ALLR) ) just unveiled an update.
On July 15, 2025, Allarity Therapeutics announced a new commercial agreement with an undisclosed EU-based biotechnology company. This agreement grants the partner a non-exclusive global license to Allarity’s DRP® algorithms for breast cancer and includes laboratory services from Allarity’s Denmark facility. The deal, which includes purchase commitments for laboratory services over the next year, is seen as a validation of Allarity’s DRP® technology and its laboratory’s expertise in advanced transcriptomic testing. Although not expected to significantly impact the company’s financial outlook, the agreement highlights Allarity’s strategy to expand its DRP® platform’s industry presence and support precision oncology solutions.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.
Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.
To see Spark’s full report on ALLR stock, click here.
More about Allarity Therapeutics
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company is primarily engaged in the development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, utilizing its proprietary DRP® technology to enhance patient selection for treatment. Headquartered in the U.S. with a research facility in Denmark, Allarity is committed to addressing unmet medical needs in cancer treatment.
Average Trading Volume: 661,846
Technical Sentiment Signal: Sell
Current Market Cap: $15.83M
For an in-depth examination of ALLR stock, go to TipRanks’ Overview page.